No profile data available.
SK Biopharmaceuticals Co., Ltd. (326030.KS) is a healthcare company in the brain and nerve treatment drugs industry, based in Seongnam-si, South Korea.
It reported revenue of 547.60 billion KRW for fiscal year 2024, up 54.3% from fiscal year 2023, and net income of 240.74 billion KRW. In Q3 2025 (the quarter ended September 30, 2025) revenue was 191.73 billion KRW, up 40.4% from a year before. United States of America was its largest region in fiscal year 2025, with 91% of revenue. Its market capitalization was 5.69 trillion KRW as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 8, 2026.
, a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication.
SK Biopharmaceuticals reported 547.60 billion KRW in revenue for fiscal year 2024, up 54.3% from 354.89 billion KRW in fiscal year 2023. In Q3 2025 revenue was 191.73 billion KRW.
United States of America: 91% of revenue by region in fiscal year 2025, followed by Switzerland (5%).
5.69 trillion KRW as of October 8, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Whan In Pharm Co.,Ltd. (016580.KS), Korean Drug Co., Ltd. (014570.KQ), Shaperon Inc. (378800.KQ).